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Abstract
Background: The presence of autoantibodies is considered an important characteristic of rheumatoid arthritis (RA);
therefore, both anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF) are included in the 2010
classification criteria for rheumatoid arthritis (RA). However, a considerable number of RA patients lack both these
autoantibodies. Recently, several novel autoantibodies have been identified but their value for the classification of
RA patients is unclear. Therefore, we studied the value of novel autoantibodies using the presence of
anticarbamylated protein (anti-CarP) antibodies as an example for predicting RA development in patients with
undifferentiated arthritis (UA).
Methods: There were 1352 UA patients included in the Leiden Early Arthritis Clinic (EAC) cohort according to the
1987 criteria. When the 2010 criteria were used, there were 838 UA patients. Of these, we evaluated whether they
fulfilled the 1987 or 2010 criteria after 1 year, respectively. Logistic regression analyses were performed with RA as
outcome and ACPA, RF, and anti-CarP antibodies as predictors. Analyses were repeated after stratification for ACPA
and RF.
Results: Thirty-three percent of the 1987-UA patients and 6% of the 2010-UA patients progressed to RA during the
first year of follow-up. For the 1987-UA patients, anti-CarP antibodies were associated with progression to RA, an
association which remained when a correction was made for the presence of ACPA and RF (odds ratio (OR) 1.7,
95% confidence interval (CI) 1.2–2.4). After stratification for ACPA and RF, anti-CarP antibodies were associated with
progression to RA only for ACPA- and RF-negative patients (OR 2.1, 95% CI 1.3–3.7). For the 2010-UA patients, anti-
CarP antibodies were associated with progression to RA; however, they were not when a correction was made for
the presence of ACPA and RF (OR 0.8, 95% CI 0.3–2.1).
Conclusions: Our finding that anti-CarP antibodies have no additional value when RA is defined according to the
2010 criteria might be inherent to the composition of the 2010 criteria and therefore might also apply to other
novel autoantibodies. Potentially it would be interesting to evaluate other, non-autoantibody biomarkers.
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Background
Rheumatoid arthritis (RA) is characterized by the pres-
ence of autoantibodies, the most characteristic among
which are anticitrullinated protein antibodies (ACPA)
and rheumatoid factor (RF). These are used as diagnostic
tools and are included in the classification criteria for
RA [1]. Nonetheless, in approximately one-third of early
RA patients these autoantibodies are lacking [2]. It is im-
portant to better characterize these patients since early
intervention in seronegative RA is also important.
Therefore, research has focused on identifying novel
autoantibodies and several have been identified [3–7].
Based on this research, two issues have been raised.
First, stratified analyses are pivotal to prove an additive
value of a test. A novel autoantibody should predict an
outcome in patients negative for both ACPA and RF, or
in patient groups with a similar presence of ACPA and/or
RF (e.g., ACPA+RF+novel autoantibody+ vsACPA+RF
+novel autoantibody- patients). Thus far, studies that have
evaluated the predictive value of novel autoantibodies are
often stratified for ACPA but not for RF, leaving the ques-
tion unanswered if the findings attributed to the novel
autoantibody were actually driven by the concomitant
presence of RF [5, 8]. A second issue is that, although dif-
ferent disease stages of RA have been studied, the value of
novel autoantibodies in identifying the patients that will
develop RA among patients presenting with undifferenti-
ated arthritis (UA) is undetermined. Only one study evalu-
ated the role of novel autoantibodies (UH-RA.1, UH-RA.
21) in UA patients as an early marker of RA development
[4]. The ultimate aim of this study was to increase our un-
derstanding on the value of recently identified autoanti-
bodies to predict RA development using accurate
stratification for ACPA and RF. An interesting novel fam-
ily of autoantibodies are the anticarbamylated protein
(anti-CarP) antibodies which target proteins modified by
carbamylation. These antibodies are present in RA pa-
tients and are associated with the severity of radiographic
progression [7, 9]. In this study, we investigated the value
of the novel anti-CarP antibodies in predicting RA devel-
opment in patients with UA, independent of ACPA and
RF [7].
Methods
Patients
Between 1993 and 2015, 1352 UA patients (according
to the 1987 criteria; 1987-UA) were included in the
Leiden Early Arthritis Clinic (EAC) cohort. This be-
came 838 UA patients when the 2010 criteria were
used (2010-UA). The EAC is an inception cohort that
was started in 1993 and includes patients with clinically
confirmed arthritis with symptom duration < 2 years at
presentation to the rheumatologist [10]. Baseline ques-
tionnaires, joint counts, and blood samples were collected,
and radiographs were taken. Two weeks after inclusion,
when the results of laboratory investigations and radiog-
raphy were known, patients received their diagnosis. Clas-
sification criteria were only applied to patients with a
clinical diagnosis or suspicion of RA, and patients who
were not classified according to RA classification criteria
were documented as having UA.
Anti-CCP2, RF, and anti-CarP measurements
Baseline serum samples were tested for ACPA, RF, and
anti-CarP antibodies. Immunoglobulin (Ig)G antibodies
to cyclic citrullinated peptide (CCP) were measured by
second generation anti-CCP2 enzyme-linked immuno-
sorbent assay (ELISA; Immunoscan RA Mark 2,
Eurodiagnostica, Arnhem; cut-off 25 U/ml), and anti-
CCP2 ELISA (EliA CCP, Phadia, Nieuwegein, the
Netherlands; cut-off 7 U/ml). IgM RF was determined by
an in-house ELISA. IgG anti-CarP antibodies were deter-
mined as described previously in the Leiden EAC [7]. As
no commercial kit is available for anti-CarP antibodies,
we used our own in-house anti-CarP assay based on car-
bamylated fetal calf serum and, as a control, nonmodi-
fied fetal calf serum as the coating antigens in the
ELISA. Cut-off for positivity was based on the mean + 2
standard deviations (SDs) from a set of healthy controls.
Analyses
Analyses were first performed when RA was classified
using the 1987 criteria; thereafter, analyses were repeated
using the 2010 criteria since autoantibodies are more
prominent in the 2010 criteria. Fulfilment of the 1987
criteria and 2010 criteria was evaluated after 1 year of
follow-up for the 1987-UA and 2010-UA patients, re-
spectively. Logistic regression analyses were performed
with ACPA, RF, and anti-CarP antibodies as independent
variables and RA as outcome, both in the total group of
UA patients and after stratification for ACPA and RF
status.
Results
Baseline characteristics of the 1352 1987-UA and 838
2010-UA patients are shown in Table 1. Of these UA pa-
tients, 33% (441/1352) and 6% (53/838) progressed to
RA during the first year according to the 1987 and 2010
criteria, respectively. Of the 1352 1987-UA patients, 257
(19%) were anti-CarP positive and of the 838 2010-UA
patients, 77 (9%) were anti-CarP positive.
The value of anti-CarP antibodies was first studied in
the 1987-UA patients. The presence of anti-CarP anti-
bodies at baseline was associated with progression to RA
(odds ratio (OR) 4.2, 95% confidence interval (CI) 3.2–5.
6), an association which remained when a correction
was made for the presence of ACPA and RF (OR 1.7,
95% CI 1.2–2.4). There was no additional predictive
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value of anti-CarP antibody levels in anti-CarP-positive
patients. The association of anti-CarP antibodies with
progression to RA was then determined within the strata
of patients with a similar ACPA and RF status. The ma-
jority of the UA patients (69%) were ACPA- and RF-
negative; 7% (65/929) of these ACPA- and RF-negative
patients had anti-CarP antibodies (Table 2). Within this
subgroup, the presence of anti-CarP antibodies was sta-
tistically significantly associated with progression to RA
(OR 2.1, 95% CI 1.3–3.7; Table 2). When absolute risks
Table 1 Baseline characteristics of the total group of UA patients and the subgroups of patients with UA according to the 1987 and
the 2010 criteria
Total group of UA patients Subgroup of 1987 UA patients Subgroup of 2010 UA patients
(n = 1430) (n = 1352) (n = 838)
Age (years), mean (SD) 53 (17) 53 (17) 51 (17)
Female, n (%) 882 (62) 837 (62) 494 (59)
Symptom duration (weeks), median (IQR) 14 (6-31) 14 (6-31) 12 (5-28)
66-SJC, median (IQR) 3 (1-7) 3 (1-7) 2 (1-4)
68-TJC, median (IQR) 4 (1-10) 4 (1-10) 2 (1-5)
CRP (mg/ml), median (IQR) 8 (3-22) 8 (3-22) 6 (3-19)
ACPA positivity, n (%) 297 (21) 283 (21) 48 (6)
RF positivity, n (%) 374 (26) 359 (27) 68 (8)
anti-CarP positivity, n (%) 271 (19) 257 (19) 77 (9)
Of the total group of UA patients (n = 1430), 760 patients have UA both according to the 1987 and 2010 criteria, 592 patients only have UA according to the 1987
criteria, and 78 patients only have UA according to the 2010 criteria
ACPA, anticitrullinated protein antibodies; anti-CarP, anticarbamylated protein antibodies; CRP, C-reactive protein; IQR, interquartile range; RF, rheumatoid factor;
SD, standard deviation; SJC, swollen joint count; TJC, tender joint count; UA, undifferentiated arthritis; symptom duration, time between symptom onset and
inclusion in cohort
Table 2 Proportion of 2010-UA and 1987-UA patients progressing to RA within 1 year within groups of similar ACPA and RF status
RA No RA % RA/% non-RA development
(pre-test risks)a
OR (95% CI) PPV (95% CI) NPV (95% CI)
1987-UA patients (n = 1352)
ACPA–RF– (n = 929) anti-CarP+ 23 42 21/79 2.1
(1.3–3.7)
35
(25–48)
80
(77–82)
anti-CarP– 176 688
ACPA+RF– (n = 64) anti-CarP+ 16 10 50/50 2.2
(0.8–6.1)
62
(43–78)
58
(42–72)
anti-CarP– 16 22
ACPA–RF+ (n = 140) anti-CarP+ 8 9 39/61 1.4
(0.5–4.0)
47
(26–69)
62
(53–70)
anti-CarP– 47 76
ACPA+RF+ (n = 219) anti-CarP+ 107 42 71/29 1.2
(0.6–2.2)
72
(64–78)
31
(22–43)
anti-CarP– 48 22
2010-UA patients (n = 838)
ACPA–RF– (n = 755) anti-CarP+ 1 48 4/96 0.5
(0.1–3.5)
2
(0–11)
96
(94–97)
anti-CarP– 30 676
ACPA+RF– (n = 15) anti-CarP+ 1 2 13/87 5.5
(0.2–129)
33
(6–79)
92
(65–99)
anti-CarP– 1 11
ACPA–RF+ (n = 35) anti-CarP+ 0 4 17/83 Undefined 0
(0–49)
81
(64–91)
anti-CarP– 6 25
ACPA+RF+ (n = 33) anti-CarP+ 9 12 42/58 1.1
(0.2–4.4)
43
(24–63)
58
(32–81)
anti-CarP– 5 7
Patients were stratified according to the presence of different autoantibody combinations (ACPA–RF–, ACPA+RF–, ACPA–RF+, and ACPA+RF+); within these groups
the predictive value of the presence of anticarbamylated protein (anti-CarP) antibodies for progression to rheumatoid arthritis (RA) was determined, both within
2010-undifferentiated arthritis (UA) and 1987-UA patients
ACPA, anticitrullinated protein antibodies; CI, confidence interval; NPV, negative predictive value; OR, odds ratio; PPV, positive predictive value; RF,
rheumatoid factor
a Observed risk of RA development within ACPA and RF strata (pre-test risks), without information on anti-CarP status
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were examined, the pre-test risk for RA development in
the ACPA- and RF-negative subgroup was 21%, and this
increased to 35% when anti-CarP antibodies were
present (Table 2). When exploring the negative predict-
ive value (NPV), the pre-test risk of not developing RA
was 79% which was similar to the NPV of 80%.
Next, the predictive value of anti-CarP antibodies was
studied within the 2010-UA patients. Here, anti-CarP
antibodies at baseline were associated with progression
to 2010 RA within 1 year (OR 2.9, 95% CI 1.4–5.8).
However, when adjustment was made for the presence
of ACPA and RF, there was no additive predictive value
of anti-CarP antibodies (OR 0.8, 95% CI 0.3–2.1). When
analyzing groups of patients stratified according to the
absence of ACPA and RF, the majority of 2010-UA pa-
tients were ACPA- and RF-negative (90%) and only 6%
(49/755) of these patients had anti-CarP antibodies.
Within this subgroup, no predictive value of anti-CarP
antibodies was observed (Table 2). Evaluation of absolute
risks in the ACPA- and RF-negative subgroup revealed
that the pre-test risk of developing RA was 4% and the
positive predictive value (PPV) was 2% when anti-CarP
antibodies were present. Likewise, the pre-test risk of
not developing RA in this subgroup was similar to the
post-test risk (NPV) when patients tested negative for
anti-CarP antibodies (both 96%, Table 2).
Discussion
This study was performed to increase our understand-
ing of the value of recently identified autoantibodies
to predict RA development using accurate stratifica-
tion for ACPA and RF. Anti-CarP antibodies were
studied as an example. We observed that the presence
of anti-CarP antibodies was statistically significantly
associated with the development of RA within ACPA-
and RF-negative 1987-UA patients. In this group, the
risk of developing RA increased from 21% to 35%
when anti-CarP antibodies were present. However,
when RA was defined according to the 2010 criteria,
anti-CarP antibodies were not associated with RA de-
velopment and the presence of these autoantibodies
did not increase the risk of RA development com-
pared to the pre-test risks.
Although they used different study designs and en-
tire early arthritis populations, two previous studies
found 2.2% and 0.4% improved classification when
adding anti-CarP to ACPA and RF, thus showing little
additive benefit [8, 11]. These findings are in line
with our data.
Presumably this finding is explained by the fact that
ACPA and RF are heavily weighted in the 2010 criteria.
Consequently, the majority of UA patients are ACPA-
and RF-negative and these patients can only fulfill the
2010 criteria if they develop > 10 involved joints but they
can fulfill the 1987 criteria over time with less extensive
disease progression; hence the definition of the outcome
matters. Additionally, autoantibodies frequently occur
together (Fig. 1), as has been shown for several novel
autoantibodies [3, 5]. These two explanations might also
apply to other novel autoantibodies. Although novel
autoantibodies other than anti-CarP antibodies were not
evaluated here, we anticipate that similar findings will be
obtained. Importantly, our findings relate to the earlier
identification of patients with RA; novel autoantibodies
can still be useful for other outcomes, such as radio-
graphic progression [7].
Conclusions
More research is needed to identify early RA patients
among (2010 criteria-negative) UA patients, but based
on the composition of the current classification criteria
Fig. 1 Concomitant presence of anticitrullinated protein antibodies (ACPA), rheumatoid factor (RF), and anticarbamylated protein (anti-CarP)
antibodies in patients with 1987-undifferentiated arthritis (UA) and 2010-UA. Depicted are the percentages of the 1352 1987-UA (a) and the 838
2010-UA (b) patients positive for ACPA, RF, and/or anti-CarP antibodies
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it will be interesting to evaluate other, non-autoantibody
biomarkers.
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